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Routine haemodialysis use is not capable of eliminating all toxic substan-
ces from uraemic patient's organism because of restricted pore size of dialysis 
membranes and of binding of certain toxins with plasma proteins. That is why 
some authors (2, 3, 4) use systemically the combination of haemodialysis (HD) 
and haemoperfusion (HP) in order to eliminate toxic substances with a higher 
molecular weight as the sorbent absorbs a part of the toxins bound up with plas-
ma proteins. 
The application of this method is confined because of the high price of haemo-
perfusers which are used only once. 
The aim of the present study is the clinical assessment of the haemoperfusers 
Bulsorb 160 as created by ourselves. 
Material and methods 
Simultaneous haemoperfusion/haemodialysis (HP/HD) procedures were car-
ried out in patients with chronic renal failure (CRF) on HD. The dialysis was 
performed by using of the dialisators Haemoflow, Nephross and ND-14. The 
haemoperfuser was started prior to the haemodialysis device. The dialysis was 
performed 4 hours long at blood flow speed of over 200 ml/min. An increased he-
parinization — with 1 ml heparin more than the routine dosis with dialysis — 
was applied in our cases. Haemoperfusion devices (columns) constructed by our-
selves from plastics with filters and volume of 160 ml called Bulsorb 160 were 
used, too. The columns were filled up with sorbent — spherical activated un-
coated charcoal from the firm Mitsubishi. Sterilization was done by means of 
ethylene oxide. 
A series of clinical and laboratory indexes were assessed and demonstrated 
i n tables below. Independently performed HDs without combination with H P 
were used as controls. 
Results and discussion 
Combined HP/HD implement did not cause any significant changes in the 
blood pressure, pulse frequency and temperature of the patients (table 1). 
No febril reactions and chills could be established in our patients. Thrombo-
cyte count and fibrinogen did not show any significant changes, too, although 
the literature data about the reduction of these parameters with HP (table 2) . 
Plasma concentrations of creatinine, urea and uric acid were examirred~be-
fore and after HP/HD to determine the absorption properties towards these sub-
stances. Creatinine, uric acid and urea levels were determined after the column 
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T a b l e 1 
Body temperature Arterial blood pressure kPa Pulse frequency 
Patfent Age 

































T a b l e 2 
Thrombocytes—giga/1 Fibrinogen g/1 
Patient Date before 
HP/HD after HP/HD before HP/HD after HP/HD 
M. к . 
D. N. 
M. K. 
J . K. j 
May 7, 1983 
May 9, 1983 i 
May 10, 1983 















T a b l e 3 
Creatinine mkmol/l Uric aric mkmol/l 
start final start final 
Patient 
Input output input output input output input output 
M. K. 724 127 ЗЗ9 161 667 155 262 137 
D. N . 1009 159 479 202 571 83 232 119 
M. K. 897 126 504 239 8ЗЗ 113 464 209 
J . K. 796 204 354 186 512 321 321 244 
T a b l e 4 
Start HP/HD F i n a l HP/HD 
Index 
HP input HP output H D output H P input HP output HD output 
Creatinine 770 271 202 354 310 189 
mkmol/1 
U r i c acid 511 400 З2З З2З 261 243 
mkmol/1 
Urea 38 31 15 20 18 8 
mmol/1 
in one patient in order to define more precisely the absorption capacity of the 
column Bulsorb 160 (table 3 and table 4). 
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It can be seen that the absorption capacity of Bulsorb 160 is considerable 
towards creatinine, less expressed towards uric acid and insignificant towards 
urea at the beginning of H P . This corresponds to the literature data available 
concerning other absorption devices filled up with an activated charcoal. At the 
end of HP/HD procedure after 4 hours absorption capacity is considerably redu­
ced, i . e. the sorbent is saturated. 
On the basis of our investigation it can be concluded that haemoperfusion 
module Bulsorb 160 possesses good absorption properties, it is biologically compa­
tible, it does not cause any side effects and can, therefore, be systemically applied 
as an addition to haemodialysis. 
R E F E R E N C E S 
1 , Д и м о в , А . , Д . Н е н о в , M. H и к о в a, X . Д и м и т р о в . Свидетелство 
за промишлен образец Булсорб 160 и Булсорб 600. София, 1983. — 2. Д м и т р и е в , 
А. А . , Е . П . Л е в и ц к и й , Н . Н . С а х а р о в а . Науч. тр. II. МОЛГМИ, т. 80, Сер. 
Хирургия, Гемосорбция, № 17, 1977, 69—73. — З. B o n o m i n i , V . , L . В а l d r a t i , 
L. С о l i , et a l . Internat. J . Artif. Organs, 1980, 3, 348, Proc. ESAO, 7, 147. — 4. S t e -
f о n i , S . , G . F е l i с i a n g е l1 i , L . С о 1 i , M. P . S с о 1 a r i , V . B o n o m i n i . 
Internat. J. Artif. Organs, 4, 1981, No 4, 189. 
К Л И Н И Ч Е С К О Е П Р И М Е Н Е Н И Е Г Е М О П Е Р Ф У З И О Н Н Ы Х УСТРОЙСТВ 
BULSORB то В К О М Б И Н А Ц И И С ГЕМОДИАЛИЗОМ 
Д. Ненов, А. Димов, Хр. Димитров, М . Никова, П. Чанкова 
Р Е З Ю М Е 
При лечении больных с хронической почечной недостаточностью методом периодичес­
кого гемодиализа происходит удаление только части уремических ядов, что связано с огра­
ниченным размером пор диализной мембраны. В результате этого ряд авторов применяет 
комбинацию гемоперфузии с гемодиализом (ГП/ГД). Этим способом достигается извлечение 
токсических субстанций, имеющих большую молекулярную массу. 
Авторы применяют комбинированный метод Г П / Г Д с использованием собственного 
устройства для проведения гемоперфузии. Это устройство заполнено сферическим, непо­
крытым активированным углем фирмы «Mitsubishi». Первые клинические испытания не дали 
побочных реакций и осложнений. Достигается хороший результат в очистке плазмы от моче­
вины, креатинина и мочевой кислоты. 
